ALCAM has been identified as a potential therapeutic target for several immune-mediated diseases, including corneal graft rejection, asthma, atopic dermatitis, food allergy, and multiple sclerosis [7,10,14,15]. The gene discussed is ALCAM; the disease is food allergy.